Bladder cancer Mature results from the KEYNOTE-045 trial were presented at ESMO 2017. The phase 3 study KEYNOTE-045 randomly assigned patients whose urothelial cancer had recurred or progressed after platinum-based chemotherapy, to either pembrolizumab (n=272) or the investigator’s choice of paclitaxel, docetaxel, or vinflunine chemotherapy (n=270). Now the 22.5 months of follow-up data confirmed a significantly longer survival in patients … Read More
Kidney Cancer Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced or Metastatic RCC. Bernard Escudier, Institut Gustave Roussy, Villejuif, France presented the results of the phase III, randomised, open-label CheckMate-214 study evaluating the combination of nivolumab and ipilimumab compared to sunitinib in patients with previously untreated advanced or metastatic RCC. Patients with measurable clear-cell metastatic RCC, Karnofsky performance … Read More
EMUC2017, the 9th Euoropean Multidisciplinary Meeting on Urological Cancers, will be held in Barcelona (Spain) from 16-19 November. EUOG will attend this congress. It might be an excellent moment to catch up with EUOG members.
Prostate cancer LATITUDE Trial: Addition of Abiraterone to Standard Hormonal Therapy Improves Outcomes in Newly Diagnosed Metastatic Prostate Cancer Karim Fizazi, Institut Gustave Roussy, Villejuif, France, presented the results of the LATITUDE Trial (Abstract LBA3). Rationale Despite androgen-deprivation therapy, the adrenal glands and prostate cancer cells continue making small amounts of androgens. Abiraterone inhibits production of testosterone throughout the body … Read More
Prostate cancer STAMPEDE Trial: Adding Abiraterone to Standard Treatment Improves Survival in Advanced Prostate Cancer Nick James, University of Birmingham, UK, presented the latest data at the 2017 ASCO Annual Meeting (Abstract LBA5003). The STAMPEDE clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the … Read More
In the meeting of the EAU Section of Oncological Urology (ESOU), on Saturday’s session ‘Critical review of robotic surgery in uro-oncology’, the EUOG will be represented. Location: Room Madrid, North Hall (Level 1) Date: Saturday, 25th March Time: 11:30 – 11:55 am Title: Circulating tumour cells in prostate cancer: A marker? ) Speaker : Susanne Osanto We cordially invite you … Read More
EAU London, March 24-28: We are there. You too? During the EAU 2017 in London, there is a scheduled EUOG meeting on Sunday, from 13.00 – 14.00 pm. We will launch the URANUS study (UTUC). If you are interested in attending this meeting, please send an email to EUOG@lumc.nl for more information or registering.
Genomic Subtyping Could Guide Treatment Decisions for Bladder Cancer Data source: Bryant Furlow, Cancer Network Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy (NAC), according to a retrospective, non-randomized study presented (abstract 281) at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium Different molecular muscle-invasive bladder cancer subtypes … Read More
This new study with the name “Neo-adjuvant versus Adjuvant chemotherapy in Upper Tract Urothelial Carcinoma: A feasibility phase II randomized clinical trial (“URANUS”)” is an exploratory randomized study. Patients who have been diagnosed with cancer in the upper urinary tract and meet the inclusion criteria, will be treated by receiving 3 cycles of neo-adjuvant or 3 cycles of adjuvant chemotherapy. A … Read More